Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Mar;48(3):1061-4.
doi: 10.1128/AAC.48.3.1061-1064.2004.

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

Agnès Lefort  1 , Juliette Pavie, Louis Garry, Françoise Chau, Bruno Fantin
Affiliations

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

Agnès Lefort et al. Antimicrob Agents Chemother. 2004 Mar.

Abstract

For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Time-kill study of dalbavancin (DAL), vancomycin (Vanco), and teicoplanin (Teico) at various concentrations against S. aureus Lim-1 (A) and Lim-2 (B) (with or without rabbit serum) and against S. aureus 218, a teicoplanin-resistant derivative of Lim-2 (C), all in BHI broth.
FIG. 2.
FIG. 2.
Mean concentrations of dalbavancin in serum following a single intravenous injection of 10 or 40 mg/kg in uninfected rabbits. Corresponding pharmacokinetic parameters of dalbavancin following administration of 10 or 40 mg/kg are shown in the embedded table.
See this image and copyright information in PMC

References

    1. Candiani, G., M. Abbondi, M. Borgonovi, M. Romano, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of BI-397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192. - PubMed
    1. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin—United States 1997. Morb. Mortal. Wkly. Rep. 46:765-766. - PubMed
    1. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. - PubMed
    1. Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI-397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254. - PubMed
    1. National Committee for Clinical Laboratory Standards. 2001. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.